News
Public · Published
CBLL: Revenue grew 30%, but higher spending widened Q3 losses as hospital adoption passed 700
Q3 revenue grew 30% year over year to $29.3M, while net loss widened to $21.4M as operating costs rose. Hospital adoption passed 700, and the company said $117.5M in cash and marketable securities supports at least 12 months of planned needs.
Published:
Updated:
What happened
Q3 revenue grew 30% year over year to $29.3M, while net loss widened to $21.4M as operating costs rose. Hospital adoption passed 700, and the company said $117.5M in cash and marketable securities supports at least 12 months of planned needs.
Confirmed
Global impact / market context
Revenue is growing, but the company still spends more than it earns, so the net loss widened. The $117.5M cash cushion means it can fund at least 12 months of planned needs without raising outside money, reducing near-term financing pressure on the stock.
Analyst inference
Investors weighing CBLL face a trade-off: fast 30% revenue growth and over 700 hospitals using the product versus a $21.4M quarterly loss. With cash covering only at least 12 months of plans, future spending and any new share sales stay central.
Analyst inference
What to watch
- Watch whether Q3 revenue keeps growing at a similar pace to the 30% year-over-year rate reported for the quarter, since slower growth alongside rising operating costs would widen losses further. Confirmed
- Company guidance would help: watch for management targets on hospital adoption beyond 700, spending plans, and how the 2026 clearances are expected to add products and revenue over coming quarters. Proposed
- Track the $117.5M in cash and marketable securities as spending rises. If losses persist, the 12-month runway shortens, which means the company may need to raise money through borrowing or share sales. Analyst inference
Evidence
- Original source link unavailable